In a cohort of 279 stage IV NSCLC patients treated with ICIs and evaluated for MET expression by CLIA-certified immunohistochemistry, we found that MET overexpression was associated with significantly improved overall and progression-free survival, contrasting with prior studies in localized or chemotherapy-treated disease. Here, MET is linked to non-small cell lung carcinoma.